Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 14/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.44 |
| ▸ | USP2 | O75604 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 6/20 | 0.38 |
| ▸ | CASP1 | P29466 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2894577 | 0.82 | FDPS (0.40) | CYP1A2CYP3A4ALDH1A1HSD17B10CYP2C19 | |
| SCHEMBL1436456 | 0.82 | FDPS (0.39) | CYP1A2CYP3A4ALDH1A1HSD17B10CYP2C19 | |
| SCHEMBL1398869 | 0.81 | FDPS (0.41) | CYP1A2CYP3A4ALDH1A1HSD17B10CYP2C19 | |
| SCHEMBL888555 | 0.81 | FDPS (0.41) | CYP1A2CYP3A4ALDH1A1HSD17B10CYP2C19 | |
| Hydrochloric Acid SCHEMBL28215610 | 0.81 | LTA4H (0.38) | CYP1A2CYP3A4ALDH1A1HSD17B10CYP2C19 | |
| SCHEMBL235438 | 0.76 | LTA4H (0.56) | CYP1A2CYP3A4ALDH1A1HSD17B10CYP2C19 | |
| SCHEMBL13281305 | 0.76 | FDPS (0.41) | CYP1A2CYP3A4ALDH1A1HSD17B10CYP2C19 | |
| SCHEMBL5495655 | 0.73 | FDPS (0.42) | CYP1A2CYP3A4ALDH1A1CYP2C19CYP2C9 | |
| SCHEMBL5440115 | 0.73 | LTA4H (0.50) | CYP1A2CYP3A4ALDH1A1HSD17B10CYP2C19 | |
| SCHEMBL23398227 | 0.72 | FDPS (0.50) | CYP1A2CYP3A4ALDH1A1HSD17B10CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118335-A1 | RNA Interference Mediated Inhibition Of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional siNA) | JADHAV VASANT | 2011-05-19 | — | — | US | disclosed |
| US-7858769-B2 | RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA) | SIRNA THERAPEUTICS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-1713915-B1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (MULTIFUNCTIONAL siNA) | SIRNA THERAPEUTICS INC (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20080039412-A1 | Rna Interference Mediated Inhibition of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina) | SIRNA THERAPEUTICS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| EP-1713915-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (MULTIFUNCTIONAL siNA) | Sirna Therapeutics, Inc. (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050233329-A1 | Inhibition of gene expression using duplex forming oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
| WO-2005078097-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA) | SIRNA THERAPEUTICS, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118335-A1 | RNA Interference Mediated Inhibition Of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional siNA) | SRRT, AGO2, SIN3A | CYP1A2 4758/4885CYP3A4 4880/4885ALDH1A1 3122/4885 |
| US-20050233329-A1 | Inhibition of gene expression using duplex forming oligonucleotides | SRRT, DDX21, DERA | CYP1A2 4627/4885CYP3A4 4877/4885ALDH1A1 2992/4885 |
| US-20080039412-A1 | Rna Interference Mediated Inhibition of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina) | SRRT, AGO2, SIN3A | CYP1A2 4758/4885CYP3A4 4880/4885ALDH1A1 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.